Navigation Links
Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting
Date:12/2/2009

n cancer cells, a protein that acts as a central regulator of tumor cell division, blood vessel growth and cell metabolism. Everolimus is being studied in multiple tumor types, including breast cancer, neuroendocrine tumors, gastric cancer, hepatocellular carcinoma (HCC) and non-Hodgkin lymphoma (NHL), as well as tuberous sclerosis complex (TSC).

As an investigational compound, the safety and efficacy profile of everolimus has not yet been established in these cancer and tumor types. Access to everolimus for these cancer and tumor types is available through carefully controlled and monitored clinical trials. These trials are designed to better understand the potential benefits and risks of the compound. For more information about everolimus clinical trials, healthcare professionals can visit www.theWIDEprogram.com. Because of the uncertainty of clinical trials, there is no guarantee that everolimus will ever become commercially available for these cancer and tumor types anywhere in the world.

Afinitor (everolimus) tablets important safety information

Afinitor is contraindicated in patients with hypersensitivity to everolimus, to other rapamycin derivatives or to any of the excipients. Potentially serious adverse reactions to Afinitor include non-infectious pneumonitis and infections, for which patients should be monitored carefully and treated as needed. In addition, non-infectious pneumonitis may require temporary dose reduction and/or interruption or discontinuation. Patients with systemic invasive fungal infections should not receive Afinitor. Oral ulceration is a common side effect of Afinitor. Renal function, blood glucose, lipids and hematological parameters should be evaluated prior to the start of therapy with Afinitor and periodically thereafter. Strong or moderate CYP3A4 or P-glycoprotein inhibitors should be avoided. An increase in the dose of Afinitor is
'/>"/>

SOURCE Novartis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
2. DEFLUX(R) Significantly Reduces Urinary Tract Infections in Children With Vesicoureteral Reflux
3. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
4. Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
5. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
6. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
7. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
8. Study Shows Vasopressin Receptor Antagonist VAPRISOL(R) (Conivaptan Hydrochloride Injection) Significantly Increased Serum Sodium Concentration in Patients with Euvolemic & Hypervolemic Hyponatremia
9. DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study
10. FASgen Announces Significant Milestone in Its Cancer Drug Development Program
11. New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4
... YORK, Oct. 17, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0487169/Novo-Nordisk-A/S-PharmaVitae-Profile.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=NoCategory ... the historical and forecast performance for Novo ...
... Inc. (NASDAQ: ANDS ) today announced that it has ... (SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger ... outstanding shares of common stock of Anadys at USD 3.70 per ... represents a 256% premium over the closing price of USD 1.04 ...
Cached Medicine Technology:Novo Nordisk A/S: PharmaVitae Profile 2Anadys Announces Agreement To Be Acquired By Roche 2Anadys Announces Agreement To Be Acquired By Roche 3Anadys Announces Agreement To Be Acquired By Roche 4
(Date:4/17/2014)... has found that India,s shocking rates of suicide are ... are clinging to tiny smallholdings less than one ... as cotton and coffee, that are highly susceptible to ... of previous case studies that point to a crisis ... ,liberalisation, of the nation,s economy during the 90s. Researchers ...
(Date:4/17/2014)... adrenaline after they suffer a cardiac arrest outside of ... long-term, according to new research conducted at St. Michael,s ... a cardiac arrest get adrenaline, which has been the ... Dr. Steve Lin, an emergency physician and trauma team ... treatment, long-term survival rates of patients who suffer a ...
(Date:4/17/2014)... that lost its status as the leading weapon against ... of life, with new research indicating it simply needs ... the use of the cheap anti-malarial drug chloroquine in ... lives of more than half a million people each ... malaria has developed resistance to chloroquine, but research carried ...
(Date:4/16/2014)... , STANFORD, Calif. Consider the marvel of the embryo. ... shape and function as they multiply to become the cells ... tissues of the body. , Now, in a feat of ... the complex genetic coding that allows embryonic cells to proliferate ...
(Date:4/16/2014)... 2014): Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today ... CDX-1401 in solid tumors, including long-term patient follow-up, have ... 6 Issue 232). The data demonstrate robust antibody and ... patients with very advanced cancers and suggest that CDX-1401 ...
Breaking Medicine News(10 mins):Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 2Health News:New evidence of suicide epidemic among India's 'marginalized' farmers 3Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2Health News:Scientists find new way to fight malaria drug resistance 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 2Health News:Stanford scientists develop 'playbook' for reverse engineering tissue 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4
... ... new book “A must have...The Maroema Cook Book” by Mamta Reid of Tokyo’s MAROEMA Vegetarian ... (PRWEB) May 6, ... new inspiration with the release of “A must have...The Maroema Cook Book” by Mamta Reid. ...
... heart disease and stroke rates in China will rise ... aging population and other increased risk factors, without policies ... smoking, according to research from Columbia University Medical Center ... an American Heart Association journal. "China,s standard of ...
... events , WEDNESDAY, May 5 (HealthDay News) -- A ... significantly cuts down on hospital drug errors, researchers from ... "We had the opportunity to design and implement a ... the hospital gets the right medication at the right ...
... Researchers at the University of Toronto have discovered a ... number of genes to generate enormously complex organs such as ... in the journal Nature entitled "Deciphering the Splicing ... Benjamin Blencowe of the University of Toronto describes how a ...
... Nausea in pregnant women tends to fade after the ... it can be a sign of flu, researchers at UT ... women who sought medical care. "People don,t necessarily think ... vomiting, but our study showed that they are common with ...
... finds , WEDNESDAY, May 5 (HealthDay News) -- People who,ve ... face an increased risk for heart complications and death if ... study has found. , "We looked at the risks connected ... Nicholas L.M. Cruden, a former cardiology lecturer at the University ...
Cached Medicine News:Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 2Health News:Unique and Nutritious Vegetarian Recipes Featured in Newly Released Hand-Bag Friendly “A must have...The Maroema Cook Book” 3Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 2Health News:China facing public health crisis with projected increase in cardiovascular disease by 2030 3Health News:Bar Codes Cut Down on Hospital Medication Errors 2Health News:Bar Codes Cut Down on Hospital Medication Errors 3Health News:U of T researchers crack 'splicing code,' solve a mystery underlying biological complexity 2Health News:Nausea and speeding heart can be signs of flu in pregnant women 2Health News:Risks Rise for Other Surgeries After Stent Implants 2
... Acid is a non-irritating rapid exfoliator. Lactic Acid ... to peel and exfoliating agents in skin care ... other exfoliators for a long period and want ... occurring human metabolite, and combined with the chemical ...
... is available in two innovative formulations: Level ... active). The Level I (40% active) formulation ... extract, which DCL scientists have identified and ... and calm the skin while the beneficial ...
... CosmoDerm and CosmoPlast are dermal fillers ... acne scars and other soft tissue contour ... of the lip border. The collagen in ... dermal tissue that is grown under controlled ...
... is a gel of ... species of bacteria, chemically ... suspended in phosphate,buffered saline ... and concentration of 20 ...
Medicine Products: